Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 63.13% is in line with its 5-year average of 62.29%, near the high end of its 5-year range (30.16%–73.48%).
13.52% above its 12-month average of 55.61%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 59.73%.
GROSS MARGIN
63.13%
GROSS MARGIN AVG TTM
55.61%
GROSS MARGIN AVG 3Y
62.35%
GROSS MARGIN AVG 5Y
62.29%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+13.52%
CURRENT VS 3Y AVG
+1.25%
CURRENT VS 5Y AVG
+1.36%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 692 covered companies
CURRENT VS SECTOR MEDIAN
+56.34%
vs the sector median at left
Market Cap
$145.88M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
12.53%
5Y Avg
23.21%
Market Cap
$140.03M
Gross Margin
57.63%
TTM Avg
59.89%
3Y Avg
61.87%
5Y Avg
62.78%
Market Cap
$139.73M
Gross Margin
62.53%
TTM Avg
65.36%
3Y Avg
65.75%
5Y Avg
64.06%
Market Cap
$139.63M
Gross Margin
81.26%
TTM Avg
40.63%
3Y Avg
20.32%
5Y Avg
13.54%
Market Cap
$146.58M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
-394.61%
5Y Avg
-639.25%
Market Cap
$148.36M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$136.88M
Gross Margin
61.99%
TTM Avg
62.83%
3Y Avg
59.84%
5Y Avg
59.96%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nyxoah S.A. (NYXH) | $143.10M | 63.13% | 55.61% | 62.35% | 62.29% |
| Immuneering Corporation (IMRX)vs › | $145.88M | 0.00% | 0.00% | 12.53% | 23.21% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $140.03M | 57.63% | 59.89% | 61.87% | 62.78% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 62.53% | 65.36% | 65.75% | 64.06% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | 81.26% | 40.63% | 20.32% | 13.54% |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.58M | 100.00% | 100.00% | -394.61% | -639.25% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.36M | 0.00% | 0.00% | 0.00% | 0.00% |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | 85.91% | 84.21% | 85.09% | 82.87% |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.88M | 61.99% | 62.83% | 59.84% | 59.96% |
| Pyxis Oncology, Inc. (PYXS)vs › | $136.44M | 82.77% | 89.91% | 44.96% | 29.97% |
Gross Margin
63.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 59.73% |
| 2026-03-31 | 30.16% |
| 2025-12-31 | 64.23% |
| 2025-09-30 | 60.50% |
| 2025-06-30 | 63.43% |
| 2025-03-31 | 61.84% |
| 2024-12-31 | 73.48% |
| 2024-09-30 | 61.93% |
| 2024-06-30 | 63.55% |
| 2024-03-31 | 62.74% |
| 2023-12-31 | 60.20% |
| 2023-09-30 | 65.57% |
| 2023-06-30 | 62.15% |
| 2023-03-31 | 60.32% |
| 2022-12-31 | 64.42% |
| 2022-09-30 | 65.38% |
| 2022-06-30 | 64.28% |
| 2022-03-31 | 56.21% |
| 2021-12-31 | 64.41% |
| 2021-09-30 | 59.61% |
| 2021-06-30 | 62.94% |
| 2021-03-31 | 71.89% |
| 2020-12-31 | -1156.52% |
| 2020-09-30 | -333.33% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
